Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (Convidecia Air®)
Product Description
CanSino Biologics Inc.
-
CN -
2024On CPHI since
-
1Certificates
-
1000 - 4999Employees
Company types
Primary activities
Categories
Specifications
CanSino Biologics Inc.
-
CN
-
2024On CPHI since
-
1Certificates
-
1000 - 4999Employees
Company types
Primary activities
More Products from CanSino Biologics Inc. (4)
-
Product Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia®
More Serogroup: Men ACWY
Long lasting: immunization memory, High affinity IgG, Mucosal immunity.
Strong Evidence: A 10-year evidence of MenACWY CRM Menhycia® evidence.
Saftey: A 10-year evidence of Men ACWY CRM Menhycia® evidence Safety of CRM 197
... -
Product Group A and Group C Meningococcal Conjugate Vaccine (CRM197) Menphecia®
• China's first bivalent meningococcal conjugate vaccine using CRM197 vector • Provides protection against two serotypes (group A and group C) • Safer and better
-
Product Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) Convidecia®
The third-generation technology
Produce humoral and cellular immunity
Stably stored and transported at 2–8°C
WHO Granted Emergency Use Listing (EUL) For Convidecia®
Approved in over 10 countries -
Product Recombinant Ebola Virus Disease Vaccine (Adenovirus Type 5 Vector)
Asia's first and World's third Ebola virus disease vaccine
The only one approved for emergency use and national stockpile in China
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance